HHS allocates $4.9M for ibogaine research

HHS allocates $4.9 million for ibogaine research

The U.S. Department of Health and Human Services (HHS) has announced a commitment of up to $4.9 million over five years to explore ibogaine and other rapid-acting treatments for mental health, particularly for veterans. This funding, managed through the Advanced Research Projects Agency for Health (ARPA-H), aims to support regulatory and manufacturing groundwork for future ibogaine trials in the United States, according to WINK News.

What the funding covers

The funding will focus on preparing Investigational New Drug Applications, securing clinical-grade ibogaine, and developing sustainable domestic manufacturing processes. However, it does not cover patient treatment, human-subject research, or authorize clinical trials. The funding is contingent upon research teams meeting accelerated milestones, with additional awards anticipated for ibogaine as a potential treatment for substance use disorders.

Research teams and objectives

ARPA-H has selected teams led by the Mark Cuban Cost Plus Drug Company, PBC, and Beond, Inc. The Mark Cuban Cost Plus Drug Company will work on establishing the regulatory and chemical foundation for a domestically manufactured ibogaine hydrochloride product. Beond, Inc. will focus on delivering clinical data regarding the safety, dosing, efficacy, and durability of ibogaine.

Broader research initiatives

In addition to the ibogaine funding, the National Institute of Mental Health has announced a $20 million initiative to support a research network for rapid-acting psychotropic drugs, including ketamine, esketamine, and psilocybin. HHS plans to announce award recipients by the summer of 2027, and all research findings will be open-sourced to accelerate further ibogaine research.

Why it matters

The initiative underscores a growing interest in psychedelic treatments for mental health issues, particularly for veterans who may benefit from new therapeutic options. HHS Secretary Robert F. Kennedy Jr. emphasized the importance of rigorous science and affordable care for veterans. The effort aligns with a directive from former President Trump to accelerate research into promising psychedelic treatments and builds on a partnership between HHS and the Department of Veterans Affairs.

HHS has acknowledged the serious safety risks associated with ibogaine, including potential heart rhythm problems, and stressed the need for participant screening and safety oversight in future clinical studies.

"Veterans deserve effective treatments and clear answers," said VA Secretary Doug Collins, highlighting the collaboration with HHS to explore ibogaine's potential.

The announcement was made shortly after Veterans Day, emphasizing the focus on veteran mental health care.